Company |
Partner |
Amt. |
Details |
Date |
TOTAL: $187.35M (YEAR TO DATE: $595.38M) | ||||
AC Immune SA (Lausanne, Switzerland) |
Roche Holdings AG (Basel, Switzerland) |
$14.30 |
Dosed the first patient in a phase I trial for Alzheimer's disease with an anti-tau monoclonal antibody |
7/8/16 |
Arena Pharmaceuticals Inc. (San Diego) |
Eisai Inc. (Woodcliff Lake, N.J.) |
$1.00 |
For Mexican regulators granted approval of weight management drug Venespri for commercialization, by Eisai Laboratorios S. de R.L. de C.V., as an adjunct to a reduced-calorie diet and increased physical activity |
7/15/16 |
Arena Pharmaceuticals Inc. (San Diego) |
Eisai Inc. (Woodcliff Lake, N.J.) |
$10.00 |
For the FDA approval of the new drug application for Belviq XR (lorcaserin HCl) CIV extended-release 20-mg tablets |
7/20/16 |
Eleven Biotherapeutics Inc. (Cambridge, Mass.) |
Roche Holdings AG (Basel, Switzerland) |
$22.50 |
For effectiveness of an IND for the interleukin-6 antagonist, EBI-031 |
7/13/16 |
Fibrogen Inc. (San Francisco) |
Astellas Pharma Inc. (Tokyo) |
$10.00 |
For dosing of the first patient in phase III trial in Japan of roxadustat for anemia in chronic kidney disease |
7/27/16 |
Heptares Therapeutics (unit of Sosei Group Corp.; Tokyo) |
Astrazeneca plc (London) |
$10 |
For the first patient being dosed in a phase I study of immuno-oncology candidate HTL-1071 (AZD4635) |
7/7/16 |
Ionis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
$10.00 |
Upon licensing IONIS-JBI1-2.5Rx, an orally delivered antisense drug for the treatment of a GI autoimmune disease; Janssen will assume all global development, regulatory and commercialization responsibilities for the compound |
7/20/16 |
Ligand Pharmaceuticals Inc. (La Jolla, Calif.) |
Wuxi Apptec (Shanghai) |
$4.00 |
One payment arose from a current Omniab licensee exercising its option to expand access to the Omniab platform; the second event arose from Wuxi Apptec sublicensing Chinese rights to an IND-ready antibody it discovered with the Omniab platform |
7/5/16 |
Morphosys AG (Martinsried, Germany) |
Novartis AG (Basel, Switzerland) |
ND |
For the initiation of a phase I trial of a Hucal antibody for the prevention of thrombosis |
7/6/16 |
Progenics Pharmaceuticals Inc. (Tarrytown, N.Y.) |
Valeant Pharmaceuticals International Inc. (Laval, Quebec) |
$50.00 |
For approval by the FDA of oral Relistor (methylnaltrexone bromide), for opioid-induced constipation in adults with chronic noncancer pain |
7/21/16 |
Progenics Pharmaceuticals Inc. (Tarrytown, N.Y.) |
Valeant Pharmaceuticals International Inc. (Laval, Quebec) |
$50.00 |
For the FDA approval of Relistor tablets to treat opioid-induced constipation in adults with chronic noncancer pain |
7/27/16 |
Vernalis plc (Winnersh, U.K.) |
Les Laboratoires Servier SAS (Suresnes, France) |
$0.55 |
Achieved a new milestone in their first oncology drug discovery collaboration, triggering a payment of €500,000 (US$550,750) to Vernalis related to success against an undisclosed target; the partners have been using Vernalis' fragment and structure-based drug discovery platform on a number of oncology targets, including Bcl-2 and Mcl-1 |
7/20/16 |
Zealand Pharma A/S (Glostrup, Denmark) |
Sanofi SA (Paris) |
$5.00 |
For FDA approval of Adlyxin (lixisenatide) in type 2 diabetes |
7/29/16 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | ||||